Investor Information

Kurve Therapeutics, headquartered in Lynnwood, WA, and Manhattan, NY, is developing disease-modifying drugs and medical technology with proven clinical efficacy in the treatment of CNS disorders including Alzheimer’s, Parkinson’s and mild cognitive aging. We are pioneering next-generation treatments for neurodegenerative diseases and striving to improve the quality of life for patients suffering from CNS disorders with limited treatment options.

An investment in Kurve Therapeutics is an investment in the future of CNS disorder treatments

The market size for CNS disorders, including mild cognitive aging and Alzheimer’s disease, is substantial and rapidly growing as the population ages. There are 121 million people over the age of 50 in the United States alone who make up the cognitive aging market.

Kurve Therapeutics is at the forefront of a new era of CNS disorder treatments. The treatment for and research into Alzheimer’s disease has remained largely the same for over 30 years — although six million people in the US live with the disease, each new lead has proven ineffective. Our cutting-edge approach has shown remarkable, disease-modifying potential. Your investment can help impact millions of people and bring new hope to those suffering from debilitating neurodegenerative disorders.

Kurve Investor Information Minimum Investment

Minimum Investment

000000

Kurve Investor Information Price Per Share

Price Per Share

000000

Kurve Investor Information Offering Circular

Offering Circular

000000

Not ready to invest? Learn more about Kurve Therapeutics by subscribing and staying up to date on our clinical trials, technology, and investment opportunities.

Bypassing the Blood-Brain Barrier: A Scientific Breakthrough

Every three seconds, someone in the world develops dementia. Current approved treatments for neurodegenerative diseases like Alzheimer’s dementia only work for around three to six months before the patient’s disease resumes progression. Why are these treatments so ineffective? They cannot penetrate the blood-brain barrier — until now.

Kurve Therapeutic’s patented Controlled Particle Dispersion (CPD)® technology is able to bypass the blood-brain barrier and deliver up to 30x more medication directly to the brain. As the first company to succeed in penetrating the BBB at these levels to date, we are changing the tide in cognitive aging and bringing new hope to those suffering from CNS disorders.

Our Controlled Particle Dispersion (CPD)® technology creates a precisely-controlled turbulent flow that allows a larger portion of disease-modifying medications to be delivered to targeted areas of the brain. Traditional intranasal delivery methods such as nasal sprays cannot access the blood-brain barrier, leaving the majority of the medication in the nasal cavity, sinuses, or GI tract. Our technology also allows for more precise dosage control, which reduces the risk of systemic side effects and does not cause nasal cavity deterioration or nasal tissue damage.

Kurve Therapeutics has over a dozen peer-reviewed publications of clinical trials using Kurve’s technology with further publications pending. We have recent and ongoing collaborations with leading research centers including Harvard, Johns Hopkins, and the Karolinska Institute. We are also proud participants in the compassionate use program.

Phase III ready

We are currently scheduled for Phase III clinical trials in three separate studies. Approximately 75% of treatments entering clinical trials do not make it to Phase III. Kurve’s remarkable clinical success thus far coupled with our Phase-III-ready status offers a unique opportunity to be a part of revolutionizing the treatment of CNS disorders.

Kurve Investor Information Featured Product Image 1

Vinase™: Intelligent Delivery, the Future of CNS Treatments

Kurve Investor Information Featured Product Image 2

Kurve offers a new, disease-modifying approach to treating CNS disorders with our Controlled Particle Dispersion (CPD)® technology. The Kurve device has been introduced into over 30 clinical trials. Our medtech innovation features:

  • Reduced systemic side-effects by ensuring less medication reaches non-targeted areas
  • Enhanced opportunity for bioavailability: delivers droplets that rest below the zone of ciliated action (the clearance mechanism of the nasal mucosa), allowing for longer residence time, which improves absorption and accelerates onset of action
  • Greater dosage precision through programmable electronic circuitry and advanced mechanics, which deliver the intended, precise amount of medication while enhancing concentration in the desired area within the nasal cavity
  • Exceptional patient compliance: Kurve’s CPD® device is non-invasive, simplified, and features user-friendly modes of administration, all of which encourage patient acceptance and use while minimizing application errors
  • Odorless, tasteless, and painless delivery of medication
  • Device is pocket-size, lightweight, portable, and battery-powered
  • Medication administration made easy: a typical dosage is taken twice daily for about 15 seconds each time

To learn more about the patented Controlled Particle Dispersion® technology, download the Investor Deck.

Investor Resources

Clinical Trials

Review Kurve’s Clinical Trials to learn more about our groundbreaking work in neurodegenerative disorder treatments.

Press Releases

Stay up to date on Kurve news, press releases, and updates.

Investor FAQs

Find answers to investors’ frequently asked questions.

Upcoming Events & Appearances

Stay up to date on upcoming events, speaking engagements, and review past appearances, to learn more about Kurve Therapeutics.

Medtech Innovators

Meet the team behind the breakthrough.

Kurve Investor Information Marc Giroux

As a serial entrepreneur and founder of five companies, Marc Giroux has closed agreements with global industry-leading pharmaceutical companies — including four of the top 20 international firms.

MARC GIROUX,

Chairman & Chief Executive Officer

Kurve Investor Information Glenn Cornett

Biotech engineer, entrepreneur, and advisor, Dr. Cornett has a long, proven history of creating exponential growth within biotech companies.

GLENN CORNETT, M.D., PH.D.,

Chief Science Officer

Kurve Investor Information Marc Giroux

As a serial entrepreneur and founder of five companies, Marc Giroux has closed agreements with global industry-leading pharmaceutical companies — including four of the top 20 international firms.

MARC GIROUX,

Chairman & Chief Executive Officer

Kurve Investor Information Glenn Cornett

Biotech engineer, entrepreneur, and advisor, Dr. Cornett has a long, proven history of creating exponential growth within biotech companies.

GLENN CORNETT, M.D., PH.D.,

Chief Science Officer

Kurve Investor Information Tom McDowell

An accomplished and highly regarded COO, Tom McDowell excels at creating organized, functional accounting structures, serving as a stabilizing force and contributing to the growth of a number of businesses across multiple industries.

Tom S. McDowell,

Chief Operating Officer

Contact Us

Title/Role

Kurve Therapeutics, headquartered in Lynnwood, Washington and Manhattan, NY, is developing disease-modifying drugs and medical technology with proven clinical efficacy in the treatment of CNS disorders inclusive of Alzheimer’s, Parkinson’s and ALS. We strive to create next-generation treatments for neurodegenerative diseases and improve the quality of life for patients suffering from CNS disorders and limited treatment options.

Kurve Technology Product Overview Video Play Icon

Investor Video

Kurve Technology Product Overview Video Play Icon

Investor Pitch Deck

Investor Resources

Kurve Technology Features and Benefits Increases treatment efficacy

Investor Blogs

Read our blog to learn more about how you can invest in Kurve Therapeutics, and how you can make a real difference in the lives of CNS disorder patients.

Kurve Technology Features and Benefits Reduce side-effects

Press Releases

Stay up to date on Kurve news, press releases, and updates.

Clinical Trials

Review Kurve’s Clinical Trials to learn more about our groundbreaking work in neurodegenerative disorder treatments.

SEC Filings

Complete your due diligence by reviewing our SEC filings.

Upcoming Events & Appearances

Stay up to date on upcoming events, speaking engagements, and review past appearances, to learn more about Kurve Therapeutics.

Kurve Technology Features and Benefits Device

Investor Frequently Asked Questions

Find answers to investors’ frequently asked questions.